UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 under the

Securities Exchange Act of 1934

July 2223, 2026

Commission File Number 001-14978

SMITH & NEPHEW plc

(Registrant’s name)

Building 5, Croxley Park, Hatters Lane

Watford, England, WD18 8YE

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ✔ Form 40-F __

~~TR-1:~~Timing ~~Standard~~of ~~form~~Smith+Nephew ~~for~~second ~~notification~~quarter ofand ~~major~~first ~~holdings~~half 2026 results

~~1. Issuer Details~~23 July 2026

~~ISIN~~Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, will announce its second quarter trading and first half 2026 results for the period ended 27 June 2026 on Tuesday 4 August 2026 at 7.00am BST / 2.00am EDT. This will be followed by a conference call for financial analysts at 11.30am BST / 6.30am EDT, details of which will be published on the Smith+Nephew website at https://www.smith-nephew.com/en/who-we-are/investors.

~~GB0009223206~~ Enquiries

~~Issuer~~Investors/ ~~Name~~Analysts

~~SMITH~~ Emily &Heaven, ~~NEPHEW~~Smith+Nephew +44 ~~PLC~~(0) 7811 919437

UKCraig orBijou, Smith+Nephew +1 ~~Non-UK~~(475) ~~Issuer~~850-8282

UK Media

2.Charles ~~Reason~~Reynolds, ~~for~~Smith ~~Notification~~+Nephew +44 (0) 1923 477314

An Susan ~~acquisition~~Gilchrist or/ ~~disposal~~Ayesha ofBharmal, ~~voting~~Brunswick +44 (0) ~~rights;~~20 An7404 ~~acquisition or disposal of financial instruments~~5959

3.About ~~Details of person subject to the notification obligation~~Smith+Nephew

~~Name~~Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 17,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.

~~Bank~~ Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of ~~America~~$6.2 ~~Corporation~~billion in 2025. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

~~City~~For ofmore ~~registered~~information ~~office~~about ~~(if~~Smith+Nephew, ~~applicable)~~please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.

~~Wilmington~~ Forward-looking Statements

~~Country~~This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our ~~registered~~suppliers; ~~office~~competition ~~(if~~for ~~applicable)~~qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC's website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.

~~United~~ ◊ Trademark of ~~States~~Smith+Nephew. Certain marks registered in US Patent and Trademark Office.

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

City of registered office (if applicable)

Country of registered office (if applicable)

5. Date on which the threshold was crossed or reached

20-Jul-2026

6. Date on which Issuer notified

21-Jul-2026

7. Total positions of person(s) subject to the notification obligation

	% of voting rights attached to shares (total of 8.A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)	Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer
Resulting situation on the date on which threshold was crossed or reached	2.402237	0.770499	3.172736	26701287
Position of previous notification (if applicable)

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)	Number of direct voting rights (DTR5.1)	Number of indirect voting rights (DTR5.2.1)	% of direct voting rights (DTR5.1)	% of indirect voting rights (DTR5.2.1)
GB0009223206		139949		0.016629
US83175M2052		20076932		2.385608
Sub Total 8.A	20216881		2.402237%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument	Expiration date	Exercise/conversion period	Number of voting rights that may be acquired if the instrument is exercised/converted	% of voting rights
Right to Recall	n/a	n/a	450000	0.053471
Sub Total 8.B1			450000	0.053471%

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument	Expiration date	Exercise/conversion period	Physical or cash settlement	Number of voting rights	% of voting rights
Swaps	15/10/2027	n/a	Cash	987	0.000117
Swaps	31/07/2026	n/a	Cash	97255	0.011556
Swaps	05/05/2027	n/a	Cash	1785464	0.212155
Swaps	19/07/2027	n/a	Cash	118748	0.014110
Swaps	07/03/2029	n/a	Cash	10077	0.001197
Swaps	02/04/2027	n/a	Cash	1841725	0.218840
Swaps	15/04/2027	n/a	Cash	400601	0.047601
Swaps	15/06/2027	n/a	Cash	491	0.000058
Swaps	18/04/2028	n/a	Cash	90066	0.010702
Swaps	13/05/2027	n/a	Cash	467225	0.055517
Swaps	10/08/2026	n/a	Cash	240883	0.028623
Swaps	17/08/2026	n/a	Cash	380000	0.045153
Swaps	06/01/2027	n/a	Cash	209294	0.024869
Swaps	06/05/2030	n/a	Cash	24678	0.002932
Swaps	30/06/2028	n/a	Cash	365968	0.043486
Swaps	31/07/2028	n/a	Cash	944	0.000112
Sub Total 8.B2				6034406	0.717028%

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person Name of controlled undertaking % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold Bank of America Corporation Bank of America, National Association Bank of America Corporation BofA Securities, Inc. Bank of America Corporation U.S. Trust Co of Delaware

10. In case of proxy voting

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

If date does not apply, explain below

11. Additional Information

12. Date of Completion

21-Jul-2026

13. Place Of Completion

London, United Kingdom

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Smith & Nephew plc
		(Registrant)
Date: July 22, 2026	By:	/s/ Helen Barraclough
Date: July 23, 2026	By:	/s/ Helen Barraclough
		Helen Barraclough
		Company Secretary

Filing Compare · SMITH & NEPHEW PLC